To Be Discontinued Oral Powder Antiviral
Atazanavir Sulfate Oral Powd · 464 days since initial FDA posting
Brand: REYATAZ
FDA lists Atazanavir Sulfate Oral Powd as To Be Discontinued (Bristol Myers Squibb Co.).
No availability text on this FDA row.
Atazanavir Sulfate Oral Powder: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Atazanavir Sulfate Oral Powder
- Manufacturer
- Bristol Myers Squibb Co.
- Dosage Form
- Oral Powder
- Presentation
- Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)
- Package NDC
- 0003-3638-10
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jun 4, 2025
- Last Updated
- Jun 4, 2025
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Permanent discontinuation
Nearby, Other Atazanavir Shortage Records
FDA reason on file: Permanent discontinuation. General shortage guidance lives on the tracker hub.